BRPI0512915A - terapias de combinação utilizando inibidores benzamida do receptor p2x7 - Google Patents
terapias de combinação utilizando inibidores benzamida do receptor p2x7Info
- Publication number
- BRPI0512915A BRPI0512915A BRPI0512915-0A BRPI0512915A BRPI0512915A BR PI0512915 A BRPI0512915 A BR PI0512915A BR PI0512915 A BRPI0512915 A BR PI0512915A BR PI0512915 A BRPI0512915 A BR PI0512915A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor
- monoclonal antibody
- benzamide
- combination therapies
- treating
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 3
- 102000000589 Interleukin-1 Human genes 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 abstract 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 abstract 1
- 108010019421 Janus Kinase 3 Proteins 0.000 abstract 1
- 102000006500 Janus Kinase 3 Human genes 0.000 abstract 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 229960004238 anakinra Drugs 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 abstract 1
- 229960001940 sulfasalazine Drugs 0.000 abstract 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58394304P | 2004-06-29 | 2004-06-29 | |
| PCT/IB2005/002195 WO2006003517A1 (en) | 2004-06-29 | 2005-06-16 | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512915A true BRPI0512915A (pt) | 2008-04-15 |
Family
ID=34979502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512915-0A BRPI0512915A (pt) | 2004-06-29 | 2005-06-16 | terapias de combinação utilizando inibidores benzamida do receptor p2x7 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060018904A1 (https=) |
| EP (1) | EP1763353A1 (https=) |
| JP (1) | JP2008504363A (https=) |
| BR (1) | BRPI0512915A (https=) |
| CA (1) | CA2572119A1 (https=) |
| MX (1) | MXPA06014023A (https=) |
| WO (1) | WO2006003517A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| ATE355273T1 (de) | 2003-05-12 | 2006-03-15 | Pfizer Prod Inc | Benzamidinhibitoren des p2x7-rezeptors |
| CA2656620C (en) * | 2006-07-04 | 2018-03-13 | Genmab A/S | Cd20 binding molecules for the treatment of copd |
| GB0622472D0 (en) | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| JP5140154B2 (ja) | 2007-06-27 | 2013-02-06 | アストラゼネカ・アクチエボラーグ | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
| WO2009019503A2 (en) * | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | P2x7 antagonists for use in the treatment of mood disorders |
| JP2009092508A (ja) * | 2007-10-09 | 2009-04-30 | Norihiro Nishimoto | リウマチ治療剤の効果の予測方法 |
| GB0724258D0 (en) * | 2007-12-12 | 2008-01-30 | Glaxo Group Ltd | Novel combinations |
| TW200942246A (en) * | 2008-03-03 | 2009-10-16 | Fabio Grassi | Method of modulating T cell-dependent immune responses |
| AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| KR20110112307A (ko) * | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ６의 길항제 |
| US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
| CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| EP2542670A2 (en) | 2010-03-05 | 2013-01-09 | President and Fellows of Harvard College | Induced dendritic cell compositions and uses thereof |
| CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
| TWI598325B (zh) * | 2012-10-12 | 2017-09-11 | Ｈ 朗德貝克公司 | 苯甲醯胺類 |
| WO2015099107A1 (ja) | 2013-12-26 | 2015-07-02 | 塩野義製薬株式会社 | 含窒素６員環誘導体およびそれらを含有する医薬組成物 |
| EP3189070A4 (en) | 2014-08-04 | 2018-06-27 | Drexel University | Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same |
| US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
| WO2018074390A1 (ja) | 2016-10-17 | 2018-04-26 | 塩野義製薬株式会社 | 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4318731A (en) * | 1979-08-25 | 1982-03-09 | Nihon Nohyaku Co., Ltd. | Δ2 -1,2,4-triazolin-5-one derivatives and herbicidal usage thereof |
| AU542544B2 (en) * | 1980-03-12 | 1985-02-28 | Nippon Kayaku Kabushiki Kaisha | Tetrahydrophthalimide derivatives |
| US4766233A (en) * | 1984-06-12 | 1988-08-23 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof |
| WO1986000072A1 (en) * | 1984-06-12 | 1986-01-03 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2h,4h)-diones and sulfur analogs thereof |
| US4806145A (en) * | 1984-10-31 | 1989-02-21 | Fmc Corporation | Herbicidal aryl triazolinones |
| JPS6299368A (ja) * | 1985-10-26 | 1987-05-08 | Nippon Nohyaku Co Ltd | Δ↑２−１，２，４−トリアゾリン−５−オン誘導体及びその製法並びにその用途 |
| AU2328188A (en) * | 1987-09-23 | 1989-04-18 | Ciba-Geigy Ag | Heterocyclic compounds |
| US5411980A (en) * | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
| US5128351A (en) * | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
| US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
| CA2109524A1 (en) * | 1991-05-10 | 1992-11-11 | Prasun K. Chakravarty | Acidic aralkyl triazole derivatives active as angiotensin ii antagonists |
| SE9103397D0 (sv) * | 1991-11-18 | 1991-11-18 | Kabi Pharmacia Ab | Nya substituerade salicylsyror |
| US5686061A (en) * | 1994-04-11 | 1997-11-11 | The Board Of Regents Of The University Of Texas System | Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors |
| JP3144624B2 (ja) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| US6147101A (en) * | 1995-06-02 | 2000-11-14 | Kyorin Pharmaceutical Co., Ltd. | N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same |
| US6001862A (en) * | 1995-06-02 | 1999-12-14 | Kyorin Pharameuticals Co., Ltd. | N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same |
| JP3906935B2 (ja) * | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| US5939418A (en) * | 1995-12-21 | 1999-08-17 | The Dupont Merck Pharmaceutical Company | Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors |
| DE69706407T2 (de) * | 1996-03-29 | 2002-05-29 | G.D. Searle & Co., Chicago | META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| DE19701287A1 (de) * | 1997-01-16 | 1998-07-23 | Wernicke & Co Gmbh | Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben |
| WO1998042669A1 (en) * | 1997-03-25 | 1998-10-01 | Astra Pharmaceuticals Ltd. | Novel pyridine derivatives and pharmaceutical compositions containing them |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| SE9704272D0 (sv) * | 1997-11-21 | 1997-11-21 | Astra Pharma Prod | Novel Compounds |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| JPH11318492A (ja) * | 1998-03-09 | 1999-11-24 | Aisin Seiki Co Ltd | 蛍光発生性基質を含有する組成物 |
| US6320078B1 (en) * | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
| FR2783519B1 (fr) * | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| DE19851184A1 (de) * | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| CZ20013608A3 (cs) * | 1999-04-09 | 2002-05-15 | Astrazeneca Ab | Adamantanové deriváty |
| SE9901875D0 (sv) * | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| DE10005284A1 (de) * | 2000-02-07 | 2001-08-09 | Bayer Ag | Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen |
| HRP20020200B1 (hr) * | 2000-05-04 | 2013-06-30 | Basf Aktiengesellschaft | Fenil sulfamoil karboksamidi supstituirani uracilom |
| CA2431171A1 (en) * | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8591801A1 (es) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| ATE355273T1 (de) * | 2003-05-12 | 2006-03-15 | Pfizer Prod Inc | Benzamidinhibitoren des p2x7-rezeptors |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
-
2005
- 2005-06-16 EP EP05759633A patent/EP1763353A1/en not_active Withdrawn
- 2005-06-16 BR BRPI0512915-0A patent/BRPI0512915A/pt not_active Application Discontinuation
- 2005-06-16 JP JP2007518739A patent/JP2008504363A/ja not_active Withdrawn
- 2005-06-16 CA CA002572119A patent/CA2572119A1/en not_active Abandoned
- 2005-06-16 WO PCT/IB2005/002195 patent/WO2006003517A1/en not_active Ceased
- 2005-06-16 MX MXPA06014023A patent/MXPA06014023A/es unknown
- 2005-06-28 US US11/168,602 patent/US20060018904A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1763353A1 (en) | 2007-03-21 |
| CA2572119A1 (en) | 2006-01-12 |
| WO2006003517A1 (en) | 2006-01-12 |
| MXPA06014023A (es) | 2007-02-08 |
| US20060018904A1 (en) | 2006-01-26 |
| JP2008504363A (ja) | 2008-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512915A (pt) | terapias de combinação utilizando inibidores benzamida do receptor p2x7 | |
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| MXPA05012086A (es) | Inhibidores de benzamida del receptor p2x7. | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| BRPI0418112A (pt) | inibidores de p-38 quinase bicìclico heterocìclicos | |
| TW200607803A (en) | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | |
| WO2008064321A3 (en) | Methods of treating chronic inflammatory diseases using a gm-csf antagonist | |
| MX2009004771A (es) | Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa. | |
| WO2006023544A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| MXPA06011327A (es) | Azaindoles utiles como inhibidores de jak y otras proteinas cinasas. | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| IL173348A (en) | Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs | |
| DK1037645T3 (da) | Fremgangsmåde til fremstilling af fraktioner af nordamerikansk ginseng, produkter indeholdende disse fraktioner og deres anvendelse som immunomodulatorer | |
| NO20014131L (no) | Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MXPA05008688A (es) | Derivados tetraciclicos de pirazol como inhibidores de la cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
| IL209338A0 (en) | Pharmaceutical compositions containing anti-cd-3 antibodies | |
| BR112021022380A2 (pt) | Inibidores de jak | |
| WO2002068476A3 (en) | Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders | |
| ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen | |
| UA87494C2 (en) | Azaindoles useful as inhibitors of jak and other protein kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |